The National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports a research project titled "Dissecting the Contribution of Mis-Splicing in Cancer Phenotypes through Multi-Omic Single-Cell Approaches." The key objectives of the project are to:
-
Utilize advanced computational frameworks and single-cell sequencing approaches to characterize aberrant splicing events and identify tumor-specific isoforms in myelodysplastic syndromes (MDS) and high-grade serous ovarian cancer (HGSOC).
-
Explore the relationship between splicing regulation, genomic instability, and immune interactions within the tumor microenvironment.
-
Identify splicing-derived neoantigens as potential targets for cancer immunotherapy, addressing challenges related to neoantigen off-target effects and HLA variability.
The 2-year grant period runs from February 1, 2025 to January 31, 2027, and the research will be conducted at Weill Medical College of Cornell University in New York.
Generated 3/4/25, 4:25 AM